Ticlopidine

When ATH:
B01AC05

Characteristic.

White solid crystalline powder. Easily soluble in water, methanol, moderately soluble in methylene chloride and ethanol, sparingly soluble in acetone and insoluble in buffer solutions with pH 6,3.

Pharmacological action.
Antithrombotic, antiagregatine.

Application.

Acute myocardial infarction (and the early stages of the rehabilitation period), unstable angina, transient ischemic attacks (secondary prevention of stroke), condition after heart valve replacement, coronary artery bypass grafting (venous shunt) and angioplasty (balloon dilatation), severe peripheral arterial disease, intermittent claudication, chronic glomerulonephritis, drepanocytemia, microangiopathy in diabetes.

Contraindications.

Hypersensitivity, acute peptic ulcer, the risk of bleeding in acute gastric ulcer and duodenal ulcer, intracranial hemorrhage (incl. anamnestic indications), gyemorragichyeskii diatyez, neutropenia, thrombocytopenia, severe liver, acute hemorrhagic stroke, pregnancy, lactation (optional waiver of breastfeeding).

Restrictions apply.

Injuries, Planned surgery (required for cancellation 2 Sun); childhood.

Side effects.

Gastrointestinal disorders (diarrhea, nausea, vomiting, decreased appetite, abdominal pain, flatulence), rarely bleeding, Hemorrhagic rash, hematuria, thrombocytopenia, neutropenia (first 3 Months), heavy agranulocytosis, pancytopenia, aplasticheskaya anemia (isolated cases), dizziness, headache, noise in ears, asthenia, increase in the content of cholesterol and triglycerides in blood serum, increase in transaminases and alkaline phosphatase (in the first 1-4 months), cholestatic jaundice, rash, itch.

Cooperation.

It increases the inhibitory effect of aspirin and other NSAIDs kollagenindutsiruemuyu on platelet aggregation and increases the risk of bleeding (incl. against the background of heparin and indirect anticoagulants). Antacids, reducing absorption, reduce the concentration in plasma 18%; cimetidine, inhibiting microsomal oxidation, It lowers the ride height by 50%. On 15% reduces blood levels of digoxin, theophylline clearance. Increases in plasma concentration of phenytoin.

Overdose.

Hemorrhagic Syndrome, convulsions, gipotermiя, breathlessness, vestibular disorders. During the post-marketing trials described one case of overdose (38-old man took one off fee 6 g without any serious complications is increased bleeding time and transaminases).

Dosing and Administration.

Inside, at the time of delivery is to 250 mg 2 once a day; with good endurance dose can be increased to 750 mg / day. In renal failure dose reduction shown.

Precautions.

In the treatment desirable control of the cells of peripheral blood and the coagulation system.

Cooperation